A diagnostic system for chronic liver fibrosis

By detecting and analyzing the tertiary lymph structure and genetic testing scores in the liver, the accuracy and specificity of chronic liver fibrosis diagnosis in the prior art are solved, and the quantitative and early diagnosis of the degree of liver fibrosis is achieved. Improves the efficacy of the treatment.

CN118583834BActive Publication Date: 2024-11-22RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411027272.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-22
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and evaluate chronic liver fibrosis, especially in the early stages, and lacks specific and accurate diagnostic methods, affecting drug development and therapeutic effects.

Method used

By detecting and analyzing tertiary lymphatic structures (TLSs) in the patient's liver, including quantity and maturity, combined with genetic testing scores, a diagnostic system is provided to assist in the diagnosis and evaluation of the extent of chronic liver fibrosis.

Benefits of technology

The quantitative and reliable diagnosis of chronic liver fibrosis is achieved, which can accurately reflect the degree of liver function damage and disease progression, provide linearly related diagnostic results, and improve the accuracy of early diagnosis and targeted treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118583834B_ABST
    Figure CN118583834B_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to achieve quantification and reliable diagnosis of liver fibrosis, and provides a diagnostic system for chronic liver fibrosis disease, which is used for diagnosing or assisting in the diagnosis of the degree of chronic liver fibrosis, and is characterized in that the diagnosis result is obtained by detecting the tertiary lymphatic structure in the patient's liver, including: an image forming device, which is used to image the patient's liver tissue staining sample to obtain a sample image; an image analyzing device, which is used to analyze the sample image to obtain the analysis result of the tertiary lymphatic structure in the patient's liver, and further obtain the diagnosis result based on the tertiary lymphatic structure analysis result.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical equipment, and in particular relates to a diagnosis system for chronic liver fibrosis. Background Art

[0002] Liver fibrosis is a pathological change that occurs in most chronic liver diseases. Various pathogenic factors, including viral, alcoholic, drug-related, metabolic, autoimmune, and cholestatic, can lead to liver cell damage or death, activate multiple mechanisms such as liver repair after injury, chronic inflammatory response, and abnormal proliferation of connective tissue, and then initiate the process of liver fibrosis. This process will lead to diffuse excessive deposition and abnormal distribution of liver extracellular matrix (i.e. collagen, glycoproteins, and proteoglycans, etc.), which is the pathological repair response of the liver to chronic injury, and is also a key step in the development of various chronic liver diseases to cirrhosis and an important link affecting the prognosis of chronic liver diseases. If the damaging factors persist for a long time, fibrosis may further develop into cirrhosis or even liver malignancy.

[0003] Clinically, liver fibrosis can be diagnosed through non-invasive tests such as serological diagnostic models, conventional ultrasound, CT, MRI, elastic ultrasound and magnetic resonance elastography. However, the evaluation of liver fibrosis based on a single blood index is limited; conventional ultrasound, CT, and MRI often have no characteristic findings for early liver fibrosis, so they are not very meaningful for the early diagnosis of liver fibrosis; elastic ultrasound and magnetic resonance elastography have become the most promising methods for non-invasive diagnosis and evaluation of liver fibrosis, but a unified magnetic resonance elastography liver elasticity value for liver fibrosis of different causes has not yet been established, and the clinical application value needs to be further evaluated.

[0004] For advanced liver fibrosis and even cirrhosis, liver biopsy is still the "gold standard" for diagnosis. Liver biopsy refers to puncturing the liver and obtaining liver tissue samples, followed by microscopic histological examination and evaluation. It is currently the most accurate and reliable diagnostic method for liver fibrosis, and is also an important basis for measuring the activity of inflammation, the degree of fibrosis, and determining the efficacy of drugs. Currently, the commonly used liver tissue inflammation grading and fibrosis staging assessment systems include the Scheuer, METAVIR, and Ishak scoring systems. Their shortcomings are that the numbers in the existing scoring systems only represent a semi-quantitative assessment of a certain type of lesion, rather than an absolute quantification. The definitions of different degrees of injury such as interface hepatitis, portal inflammation, and hepatocellular damage are not linearly related, and thus cannot provide the most direct diagnostic and evaluation value.

[0005] In other words, there is no specific and effective method for diagnosing liver fibrosis in clinical practice. Therefore, how to effectively use liver puncture biopsy tissue to achieve quantification and reliable diagnosis of liver fibrosis is of great significance in the early drug development, treatment and intervention of chronic liver fibrosis.

[0006] Tertiary lymphoid structures (TLS), also known as the third lymphoid organ or ectopic lymphoid structure, are organized immune cell aggregates produced in non-lymphoid tissues under non-physiological conditions. They generally appear in chronic inflammatory tissues caused by autoimmune diseases, chronic infections, and tumors. TLS mainly contain B cells, follicular dendritic cells (FDC), T cells, fibroblast reticular cells (FRC), stromal cells, dendritic cells, neutrophils, macrophages, and endothelial cells. Among them, follicular dendritic cells (FDC) are usually located in the center of B cells, expressing various receptors, promoting antigen presentation to B cells to express highly active antibodies, while endothelial cells are located at the edge of TLS. The formation and maturation of TLS is a multi-step, dynamic process. In this process, pro-inflammatory signals derived from immune cells act as inducing factors, and activated fibroblasts act as organizers by establishing and maintaining lymphocyte structures or producing key chemokines, recruiting a variety of cells to the corresponding locations. These cells eventually differentiate and mature through extensive cell-to-cell interactions and exert immune effects. Mature TLS includes B cell areas and germinal centers surrounded by T cells. It is an important site for the interaction between tissue cells and immune cells and is closely related to the prognosis of patients with various tumors and the response to immunotherapy.

[0007] The most intensively studied area surrounding TLS is solid tumors, whose regulation of adaptive immunity is considered to be the core of anti-tumor immunity and a promising target in solid tumors and immunotherapy. As producers of tumor-specific antibodies, TLS-resident B cells may suppress tumor-specific immunity through mechanisms such as secretion of IL-10. In addition, depending on the antibody isotype produced and the type of immune cells present, tumor-specific antibodies can also inhibit tumor-specific immune responses through signals sent by inhibitory Fc receptors. Although inducing TLS formation or enhancing TLS function may improve anti-tumor immunity, such interventions may also simultaneously enhance autoreactive T and B cell responses in other tissue sites, inducing autoimmune toxicity.

[0008] Chronic liver fibrosis is not an independent disease, but a result of multiple chronic causes. However, there has been no research or application on how the formation and functional activation of TLS affect the progression of chronic liver fibrosis. Summary of the invention

[0009] The inventors of this application found that persistent inflammatory response in the liver is still the initiating factor driving the formation of fibrosis, and is the key driving force for the progression of fibrosis to cirrhosis and even liver malignancies; and chronic liver fibrosis is not an independent disease, but may be caused by a variety of different chronic causes. The inventors further found that TLS may have the effect of promoting liver inflammatory response, aggravating pathological fibrosis, and promoting liver function damage in chronic liver fibrosis caused by different causes, suggesting the potential value of TLS in the assessment and diagnosis of chronic liver fibrosis.

[0010] Based on the above findings, in order to achieve quantification and reliable diagnosis of liver fibrosis, the present invention provides a diagnostic system for chronic liver fibrosis diseases caused by different causes, which is used for diagnosing or assisting in the diagnosis of the degree of chronic liver fibrosis, and is characterized in that the diagnosis result is obtained by detecting the tertiary lymphatic structure in the patient's liver, including: an image forming device, used to image the patient's liver tissue staining sample to obtain a sample image; an analysis device, used to analyze the sample image to obtain the analysis result of the tertiary lymphatic structure in the patient's liver, and further obtain a diagnosis result based on the tertiary lymphatic structure analysis result.

[0011] The above-mentioned chronic liver fibrosis disease diagnosis system provided by the present invention may also have such a technical feature, wherein the tertiary lymphatic structure analysis result includes the number of tertiary lymphatic structures and the maturity of the tertiary lymphatic structures.

[0012] Furthermore, the above-mentioned diagnostic system for chronic liver fibrosis provided by the present invention may also have such technical features, that the liver tissue staining samples include H&E staining samples and multi-color immunofluorescence staining samples, the image forming device includes a slice scanner for scanning the H&E staining samples and a fluorescence scanner for imaging the multi-color immunofluorescence staining samples, the number of tertiary lymphatic structures is obtained by analyzing the sample images corresponding to the H&E staining samples, and the maturity of the tertiary lymphatic structures is obtained by analyzing the sample images corresponding to the multi-color immunofluorescence staining samples.

[0013] Furthermore, the maturity of the tertiary lymphoid structure in the present invention can be characterized by the number of secondary lymphoid follicle-type tertiary lymphoid structures.

[0014] In addition, the multicolor immunofluorescence staining samples in the present invention can also include fluorescent staining samples of T cell CD3, B cell CD20 and CD23, follicular cell CD21, high endothelial vein PNad, dendritic cell CD208 and cell nucleus DAPI. The sample image corresponding to the multicolor immunofluorescence staining sample is obtained by superimposing the imaging images corresponding to each fluorescent staining sample.

[0015] In addition, the diagnostic system for chronic liver fibrosis of the present invention may also include: a gene detection device for detecting the characteristic tertiary lymphoid structure gene set and obtaining a gene detection score based on the detection results, and an analysis device for further combining the gene detection score with the tertiary lymphoid structure analysis results to obtain a diagnosis result.

[0016] Among them, the characteristic tertiary lymphoid structure gene set of chronic liver fibrosis caused by non-alcoholic fatty liver disease can include the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6 and IGHG3.

[0017] Furthermore, the analysis device can obtain a TLS score based on the detection results of the characteristic tertiary lymphoid structure gene set of chronic liver fibrosis caused by non-alcoholic fatty hepatitis. The TLS score is used to determine whether the chronic liver fibrosis disease is diagnosed; the number of tertiary lymphoid structures and the maturity of the tertiary lymphoid structures are used to determine the degree of progression of chronic liver fibrosis diseases caused by different causes.

[0018] According to the diagnostic system for chronic liver fibrosis provided by the present invention, the diagnosis result is obtained by detecting the tertiary lymphatic structure in the liver. The tertiary lymphatic structure has the functions of promoting liver inflammatory response, aggravating pathological fibrosis, and promoting liver function damage in chronic liver fibrosis caused by different causes. It is directly related to the development of chronic liver fibrosis (the degree of fibrosis). Therefore, the detection result of the tertiary lymphatic structure can reflect the degree of chronic liver fibrosis, thereby effectively and accurately realizing the detection or auxiliary detection of chronic liver fibrosis.

[0019] Furthermore, since the number of tertiary lymphoid structures was obtained by analyzing the sample images corresponding to the H&E staining samples, and the maturity of the tertiary lymphoid structures was obtained by analyzing the sample images corresponding to the multi-color immunofluorescence staining samples, the maturity is specifically the number of tertiary lymphoid structures of the secondary lymphoid follicle type, and the number and maturity of the tertiary lymphoid structures are basically linearly correlated with the degree of chronic liver fibrosis. The number and maturity of the tertiary lymphoid structures can be used to basically quantitatively obtain the detection results of the degree of chronic liver fibrosis. Therefore, the diagnostic system for chronic liver fibrosis diseases of the present application can also accurately realize the quantitative detection of the degree of chronic liver fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a typical example diagram of sample images corresponding to H&E slices of liver tissue samples of six chronic liver fibrosis diseases in Example 1 of the present invention.

[0021] Figure 2This is a result diagram of the correlation between the number of TLS and the Ishak score in Example 1 of the present invention.

[0022] Figure 3 This is a graph showing the results of the correlation analysis between the number of TLS and the Ishak score in Example 1 of the present invention.

[0023] Figure 4 This is an imaging result diagram of different immunofluorescence staining of a tissue sample in Example 2 of the present invention.

[0024] Figure 5 Yes Figure 4 The multi-color immunofluorescence staining sample image is formed by superimposing the imaging results of different immunofluorescence staining images.

[0025] Figure 6 This is a graph showing the results of the correlation analysis between the number of SFL-TLS and the Ishak score in Example 2 of the present invention.

[0026] Figure 7 This is a graph showing the GSEA analysis results of a public dataset of transcriptome sequencing of liver tissue specimens of chronic liver fibrosis caused by different etiologies in Example 4 of the present invention.

[0027] Figure 8 This is a ROC curve analysis diagram between the chronic liver fibrosis disease group caused by different causes and the healthy control group based on TLS score in Example 4 of the present invention.

[0028] Fig. 9 4 is a working principle diagram of the chronic liver fibrosis disease diagnosis system of Example 4 of the present invention. DETAILED DESCRIPTION

[0029] The specific embodiments of the present invention are described below in conjunction with the examples. In the following examples, the reagents and materials whose sources are not indicated are purchased through conventional commercial channels, and the unindicated operating steps and condition parameters refer to the prior art in the art.

[0030] Example 1: Correlation analysis between the number of TLS and chronic liver fibrosis

[0031] This example uses liver tissue samples of chronic liver fibrosis collected clinically to analyze the correlation between the number of TLS and chronic liver fibrosis, and uses the Ishak score as a diagnostic standard for comparison. The specific process is as follows:

[0032] Liver tissue samples from 6 different causes of chronic liver fibrosis were collected, including hepatitis B virus (n=5), alcoholic (n=5), drug-induced (n=5), non-alcoholic fatty (n=5), autoimmune (n=5), and cholestatic (n=5), for a total of 30 samples. Each sample was fixed with 4% paraformaldehyde, and the tissue was dehydrated and embedded in paraffin before H&E staining of the tissue sections. The NanoZoomer S360 digital slice scanner was used to scan and obtain the sample images corresponding to the H&E sections. Each sample image was analyzed and the TLS was counted to obtain the number of TLS in each section (based on the number of TLS per 500mm 2 Then, the number of TLS in each sample was compared with the Ishak score of the corresponding patient.

[0033] Figure 1 This is a typical example diagram of sample images corresponding to H&E slices of liver tissue samples of chronic liver fibrosis diseases caused by six causes in Example 1 of the present invention.

[0034] like Figure 1 As shown, TLS structures appeared to varying degrees in the H&E slice sample images of liver tissue samples of chronic liver fibrosis caused by six different etiologies (the areas indicated by arrows in the figure).

[0035] Figure 2 is a graph showing the correlation between the number of TLS and the Ishak score in Example 1 of the present invention, Figure 2 In the figure, the ordinate represents the number of TLS and the abscissa represents the Ishak score.

[0036] Figure 3 is a graph showing the correlation analysis results between the number of TLS and Ishak scores in Example 1 of the present invention. Figure 2 The result graph after linear fitting of the data results.

[0037] like Figure 2 , Figure 3 As shown, in chronic liver fibrosis diseases caused by different etiologies, TLS-like structures are formed in the liver tissue microenvironment of the corresponding patients, and there is a significant positive correlation between the number of TLS in each liver tissue and the fibrosis index Ishak score (P<0.0001, r=0.8832).

[0038] Example 2: Correlation analysis between TLS maturity and chronic liver fibrosis

[0039] This example uses liver tissue samples of chronic liver fibrosis collected clinically to analyze the correlation between TLS maturity and chronic liver fibrosis, and uses the Ishak score as the diagnostic standard for comparison. Among them, TLS maturity is characterized by the number of secondary lymphoid follicle-type TLS (SFL-TLS). The specific process is as follows:

[0040] Referring to the above Example 1, liver tissue samples of chronic liver fibrosis induced by 6 different causes were collected, including: hepatitis B virus (n=5), alcoholic (n=5), drug-induced (n=5), non-alcoholic fatty (n=5), autoimmune (n=5), and cholestatic (n=5), a total of 30 samples.

[0041] Each sample was fixed with 4% paraformaldehyde, and the tissue was dehydrated and embedded in paraffin before tissue sectioning. Multicolor immunofluorescence staining was performed for T cell CD3, B cell CD20 and CD23, follicular cell CD21, high endothelial vein PNad, dendritic cell CD208 and cell nucleus DAPI to obtain the corresponding fluorescent staining samples. Then, the Vectra multispectral imager was used to image each fluorescent staining sample and the imaging results were superimposed to obtain the corresponding sample image.

[0042] Based on the sample images, the number of secondary lymphoid follicle-type TLS (SFL-TLS) in the liver tissue of each sample was analyzed, and then the number was compared with the Ishak score.

[0043] Figure 4 is an imaging result diagram of different immunofluorescence staining of a tissue sample in Example 2 of the present invention, Figure 5 Yes Figure 4 The multi-color immunofluorescence staining sample image is formed by superimposing the imaging results of different immunofluorescence staining images.

[0044] like Figure 5 As shown, in the sample image obtained after multi-color immunofluorescence staining and imaging overlap, the structure of SFL-TLS is very obvious (the part indicated by the arrow).

[0045] Figure 6 This is a graph showing the results of the correlation analysis between the number of SFL-TLS and the Ishak score in Example 2 of the present invention.

[0046] like Figure 7 As shown in the data, in chronic liver fibrosis caused by different etiologies, the number of SFL-TLS formed in the liver tissue of the corresponding patients was different, and there was a significant positive correlation between the number of SFL-TLS and the fibrosis index Ishak score (P<0.0001, r=0.8188).

[0047] Example 3: Diagnostic system for chronic liver fibrosis and its clinical application

[0048] As mentioned above, the number of TLS and SFL-TLS in liver tissue showed significant positive correlation with the fibrosis index Ishak score. Since the number of SFL-TLS represents the maturity of TLS, it can also be considered that the maturity of TLS also has this significant positive correlation. The reason is that under various pathological conditions such as viral, alcoholic, drug-related, metabolic, autoimmune, and cholestatic, TLS is formed in the liver microenvironment and gradually matures, which promotes liver inflammation and pathological fibrosis by regulating and activating humoral immune responses. The number of TLS in liver tissue and its maturity indicate the degree of fibrosis progression. Therefore, TLS can be used as a highly specific and sensitive biomarker for the diagnosis and auxiliary diagnosis of chronic liver fibrosis caused by different etiologies.

[0049] Based on this, this embodiment proposes a diagnostic system for chronic liver fibrosis, including: an image forming device, used to image the patient's liver tissue staining samples (including H&E staining samples and multi-color immunofluorescence staining samples) to obtain sample images; an analysis device, including a slice scanner for scanning the H&E staining samples and a fluorescence scanner for imaging the multi-color immunofluorescence staining samples, the number of TLS is obtained based on the analysis of the H&E staining samples, and the number of SFL-TLS is obtained based on the multi-color immunofluorescence staining samples as a representation of the maturity of TLS, and the degree of liver fibrosis is further obtained based on the number of TLS and the number of SFL-TLS.

[0050] When the number of TLS detected is higher, it can be diagnosed or assisted in diagnosis as a more serious degree of chronic liver fibrosis. Correspondingly, when the number of TLS detected is lower, it can be diagnosed or assisted in diagnosis as a less serious degree of chronic liver fibrosis. For example, referring to the correlation between the two and the Ishak score, the average value of the two is directly calculated as a quantitative score value, which can replace the Ishak score and other indicators in clinical practice to characterize the degree of liver fibrosis.

[0051] The specific clinical implementation process is as follows:

[0052] After excluding contraindications to liver puncture, ultrasound-guided percutaneous liver biopsy was selected: a 16 G biopsy needle was recommended, and the liver tissue strip sample should be at least 1.5 cm long; the patient was placed in a supine or left lateral position with the right side of the body close to the bedside, and the right arm was raised and bent and placed behind the pillow. Strict aseptic operation was performed, and the operator wore a mask, cap, and sterile gloves. The local skin of the puncture was routinely disinfected, and a sterile drape was spread. 2% lidocaine was locally infiltrated layer by layer to anesthetize the skin, muscles, and liver capsule at the puncture point; the patient was asked to breathe calmly, and the operator held the puncture needle and pierced the liver parenchyma under ultrasound guidance, and fired after reaching the target position; after the sampling was completed, the coaxial needle was pulled out while holding the breath, the puncture point was disinfected, covered and fixed with sterile gauze, and a multi-head abdominal band was tightly tied around the ribs and upper abdomen for at least 2 hours to apply pressure.

[0053] Fill out the pathology form: including name, age, gender, department, hospital number, site, quantity, ex vivo time, operation time and other information; flush the liver tissue sample from the needle with saline into a 1.8mL specimen tube, immediately remove part of the tissue and store it in a container containing 10% neutral formalin. The fixative should be at least 5 times the sample volume, and the fixation time should be 4-6 hours. The remaining tissue should be immediately stored in liquid nitrogen and transported to the laboratory within 24 hours for subsequent related operations.

[0054] The samples were numbered, registered, sampled, dehydrated, waxed, embedded, sliced, stained and light-protected, and the H&E staining and multicolor immunofluorescence staining steps were referred to the above-mentioned Example 1 and Example 2. Scanners were used for microscopic diagnosis, and NanoZoomer S360 digital slice scanner and Vectra multispectral imager were used for imaging scanning and TLS detection of H&E staining and multicolor immunofluorescence staining (staining reagents included CD3, CD20, CD23, CD21, PNad, CD208 and DAPI, etc.), and image analysis and recognition methods were used to statistically analyze the number and maturity of TLS in tissue sections (i.e., the number of SFL-TLS).

[0055] Among them, the image analysis and recognition means can be an image target recognition and analysis means based on machine learning, such as a neural network model. First, a large number of TLS specimen images (H&E staining images or multi-color immunofluorescence staining images) are used as training sets to train the model, so that the model can identify TLS in H&E staining images or SFL-TLS in multi-color immunofluorescence staining images, and then count them to obtain the number of TLS in the H&E staining image or the number of SFL-TLS in the multi-color immunofluorescence staining image. The specific training and other operations of this image analysis and recognition means can all adopt existing technologies and will not be repeated here.

[0056] Example 4: Diagnostic system for chronic liver fibrosis combined with gene detection and its clinical application

[0057] In this example, liver tissue of chronic liver fibrosis caused by non-alcoholic fatty hepatitis was used in combination with spatial transcriptome sequencing technology to analyze and screen out the characteristic TLS gene set for chronic liver fibrosis caused by non-alcoholic fatty hepatitis. At the same time, the public liver transcriptome sequencing data set of chronic liver fibrosis diseases caused by other different causes was used to identify the TLS characteristic gene set related to chronic liver fibrosis caused by non-alcoholic fatty hepatitis, and the related characteristic genes of TLS and their application in diagnosis were further explored.

[0058] The screening and analysis process of characteristic genes is as follows:

[0059] Spatial transcriptome sequencing was performed on liver tissue samples of 4 cases of chronic liver fibrosis caused by non-alcoholic steatohepatitis. TLS regions and non-TLS regions were identified based on H&E and multicolor immunofluorescence staining. Spots of TLS regions and non-TLS regions in liver tissues of 4 cases of chronic liver fibrosis caused by non-alcoholic steatohepatitis were extracted for differential gene analysis, and four differential gene sets with characteristic high expression in TLS regions were obtained. The top 25 genes in each differential gene set were extracted for cross-analysis, and finally 12 TLS genes with high correlation with chronic liver fibrosis were screened out, namely, 12 TLS genes characteristic of chronic liver fibrosis, as follows:

[0060] IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, S100A6, and IGHG3.

[0061] The sequences of the F primers and the R primers in the 12 pairs of primers corresponding to the above 12 characteristic genes are shown in SEQ ID NO.1 to SEQ ID NO.24, respectively, and are specifically shown in the following Table 1:

[0062] Table 1 Primer sequences of characteristic genes

[0063]

[0064] Based on the above 12 characteristic genes, this example constructs a TLS gene set characteristic of chronic liver fibrosis caused by non-alcoholic fatty liver disease, and constructs a scoring system based on the detection results of the gene set (i.e., the expression level results of each gene), and the scoring calculation method is as follows:

[0065] Firstly, the gene expression profile of transcriptome sequencing data of liver tissue samples was used to evaluate the enrichment score of the gene set using the Gene Set Variation Analysis (GSVA) ​​(DOI: 10.18129 / B9.bioc.GSVA, version 1.40.1) method, and a predefined gene set (TLS gene set characteristic of chronic liver fibrosis caused by non-alcoholic fatty hepatitis); the minimum gene set was set to 5 and the maximum gene set was set to 5000, and the enrichment score of each sample in each gene set was calculated, and finally the enrichment score (i.e., TLS score) matrix was obtained.

[0066] This example also verifies the above gene set and scoring system through transcriptome sequencing public datasets of chronic liver fibrosis caused by other different etiologies, as follows:

[0067] Eleven public transcriptome sequencing datasets were collected, including liver tissues and hepatocellular carcinoma tissues of 6 chronic liver fibrosis diseases induced by different etiologies, including: non-alcoholic fatty liver disease (NAFLD, GSE151158, n=61), non-alcoholic steatohepatitis (NASH, GSE49541, n=104), diet-induced non-alcoholic steatohepatitis mouse model (NASH, GSE207856, n=21), childhood biliary atresia (BA, GSE46960, n=95), carbon tetrachloride-induced chronic liver fibrosis mouse model (GSE152329, n=198), chronic acute hepatitis (CA), and chronic hepatitis (CA). The TLS gene set consisted of 12 genes and the GSVA analysis was performed on these datasets to obtain the corresponding TLS scores.

[0068] Figure 7 This is a graph showing the GSVA analysis results of the liver tissue specimen transcriptome sequencing public dataset of Example 4 of the present invention.

[0069] Figure 7In the figure, AJ correspond to each data set, and each ordinate is the TLS score. The abscissa HD in A represents healthy patients, and NAFLD represents non-alcoholic liver disease; the abscissa NASH-mild in B represents mild non-alcoholic steatohepatitis, and NASH-severe represents severe non-alcoholic steatohepatitis; the abscissa HD in C represents healthy patients, NAFLD represents non-alcoholic liver disease, and NASH represents non-alcoholic steatohepatitis; the abscissa NC in D represents healthy controls, and BA represents biliary atresia; the abscissa Vehicle in E represents the control group, and CCL4 represents the carbon tetrachloride experimental group ; The abscissa HD in F represents healthy patients, and HBV-ACLF represents patients with chronic hepatitis B-positive acute-on-chronic liver failure; the abscissa HD in G represents healthy patients, and HBV represents patients with chronic hepatitis B; the abscissa HD in G represents healthy patients, and AH represents patients with alcoholic hepatitis; the abscissa HD in I represents healthy patients, ACLD represents adult cholestatic liver disease, PCLD represents childhood cholestatic liver disease, ALGS represents patients with Alagille syndrome, and PAH represents childhood autoimmune hepatitis; the abscissa Normal in J represents normal controls, and HCC represents hepatocellular carcinoma.

[0070] Figure 8 This is a ROC curve analysis diagram between the chronic liver fibrosis disease group and the healthy control group based on TLS score in Example 4 of the present invention.

[0071] like Figure 7 , Figure 8 As shown in the data, the TLS scores of chronic liver fibrosis groups induced by various etiologies were significantly higher than those of the healthy control group, while the TLS scores of hepatocellular carcinoma were significantly lower than those of the normal control group.

[0072] Table 2 below shows the results of TLS score calculation for 6 chronic liver fibrosis diseases based on the TLS gene set.

[0073] Table 2 TLS score results for diagnosis of chronic liver fibrosis

[0074]

[0075] As shown in Table 2 above, the correlation between TLS score and chronic liver fibrosis can be expressed by the OR value in Table 2, or can be distinguished by the coefficient β value, p value, etc. in Table 2, among which the OR value is the most intuitive and obvious. For example, the OR value of NASH (GSE49541) is as high as 231636343.462, which has a very high correlation. Therefore, the degree of NASH liver fibrosis can be judged only by TLS score; for another example, for PAH (GSE206364), its OR value is as high as 9540555.0893; the OR value of CLD (GSE206364) reaches 7509628.248.

[0076] As described above, the TLS score calculated based on the gene set consisting of 12 characteristic genes is highly correlated with the degree of liver fibrosis, so the TLS score alone can basically achieve the effect of diagnosis or auxiliary diagnosis. Therefore, based on Example 3, further combined with genetic testing, the diagnosis result of the degree of fibrosis of chronic liver fibrosis can be accurately obtained.

[0077] Fig. 9 4 is a working principle diagram of the chronic liver fibrosis disease diagnosis system of Example 4 of the present invention.

[0078] like Fig. 9 As shown, in this embodiment, after obtaining a liver tissue strip sample by the liver biopsy operation of Example 3, a portion of the liver biopsy sample can be taken for gene detection operation while performing H&E staining and multicolor immunofluorescence staining, as follows:

[0079] Extraction and reverse transcription of RNA from liver biopsy tissue: remove the specimen tube from liquid nitrogen, ensuring that no more than 30 mg of tissue is used, add magnetic beads, and centrifuge at 4°C for 1 min using an OMINI magnetic bead tissue homogenizer. After discarding the magnetic beads, extract 30 μl of RNA using a Mini Kit (Qiagen), and measure the resulting RNA concentration using a NanoDrop 2000 ultra-micro spectrophotometer.

[0080] An appropriate amount of RNA was taken for transcriptome sequencing analysis, and the GSVA tool was used to analyze the TLS gene set composed of the aforementioned 12 characteristic genes to obtain the TLS score.

[0081] Then, the test results of Example 3 are combined with the TLS score results for comprehensive analysis to obtain a diagnosis. During diagnosis, the TLS score can be used to determine whether the diagnosis is confirmed, and the degree of chronic liver fibrosis can be further determined based on the number of TLS and the number of SFL-TLS. The specific diagnostic method is as follows:

[0082] For patients clinically suspected of NAFLD, if the TLS score in the tissue obtained by liver biopsy is higher than 0.91115, the diagnosis is considered to be confirmed; for patients clinically suspected of NASH, if the TLS score in the tissue obtained by liver biopsy is higher than -0.94578, the diagnosis is considered to be confirmed; for patients clinically suspected of HBV, if the TLS score in the tissue obtained by liver biopsy is higher than -2.9642, the diagnosis is considered to be confirmed; for patients clinically suspected of AH, if the TLS score in the tissue obtained by liver biopsy is higher than 2.1658, the diagnosis is considered to be confirmed; for patients clinically suspected of PAH, if the TLS score in the tissue obtained by liver biopsy is higher than -2.1466, the diagnosis is considered to be confirmed; for patients clinically suspected of CLD, if the TLS score in the tissue obtained by liver biopsy is higher than 0.26227, the diagnosis is considered to be confirmed. For patients clinically suspected of chronic liver fibrosis, every 500mm of the tissue obtained by liver biopsy is 2 When the number of TLS in the area is 0, liver fibrosis can be ruled out; when the number of SFL-TLS is 1-2, mild fibrosis is considered; when the number of SFL-TLS is 3-4, severe fibrosis is considered; when the number of SFL-TLS is greater than 5, cirrhosis is considered.

Claims

1. A diagnostic system for chronic liver fibrosis, used for diagnosing or assisting in the diagnosis of the degree of chronic liver fibrosis, characterized in that: The diagnosis is made by testing the tertiary lymphatic structures in the patient's liver, including: An image forming device, used for imaging the stained liver tissue sample of the patient to obtain a sample image; an analysis device, configured to analyze the sample image to obtain a result of analyzing the tertiary lymphatic structure in the patient's liver, and to obtain the diagnosis result at least based on the result of analyzing the tertiary lymphatic structure. The analysis result of the tertiary lymphatic structure includes the number of the tertiary lymphatic structures and the maturity of the tertiary lymphatic structures.

2. The diagnostic system for chronic liver fibrosis according to claim 1, characterized in that: in, The liver tissue staining samples include H&E staining samples and multi-color immunofluorescence staining samples. The image forming device includes a slice scanner for scanning the H&E stained sample and a fluorescence scanner for imaging the multi-color immunofluorescence stained sample. The number of the tertiary lymphatic structures is obtained by analyzing the sample image corresponding to the H&E stained sample. The maturity of the tertiary lymphatic structure is obtained by analyzing the sample image corresponding to the multi-color immunofluorescence staining sample.

3. The diagnostic system for chronic liver fibrosis according to claim 2, characterized in that: in, The maturity of the tertiary lymphoid structures is characterized by the number of secondary lymphoid follicle-type tertiary lymphoid structures.

4. The diagnostic system for chronic liver fibrosis according to claim 3, characterized in that: in, The multicolor immunofluorescence staining samples include fluorescent staining samples of T cell CD3, B cell CD20 and CD23, follicular cell CD21, high endothelial vein PNad, dendritic cell CD208 and cell nucleus DAPI. The sample image corresponding to the multi-color immunofluorescence staining sample is obtained by superimposing the imaging images corresponding to each of the fluorescent staining samples.

5. The diagnostic system for chronic liver fibrosis according to claim 1, characterized in that: Also includes: A gene detection device for detecting a characteristic tertiary lymphoid structure gene set of chronic liver fibrosis caused by non-alcoholic fatty hepatitis, The analysis device obtains the diagnosis result based on the analysis result of the tertiary lymphatic structure and the detection result of the characteristic tertiary lymphatic structure gene set of chronic liver fibrosis caused by non-alcoholic fatty hepatitis.

6. The diagnostic system for chronic liver fibrosis according to claim 5, characterized in that: in, The characteristic tertiary lymphoid structure gene set of chronic liver fibrosis caused by non-alcoholic fatty liver disease is composed of the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6, and IGHG3.

7. The diagnostic system for chronic liver fibrosis according to claim 5 or 6, characterized in that: in, The diagnosis results include whether it is confirmed and the degree of progression. The analysis device obtains a TLS score based on the detection result of the characteristic tertiary lymphoid structure gene set of chronic liver fibrosis caused by non-alcoholic fatty hepatitis, and the TLS score is used to determine whether the diagnosis is confirmed. The number of the tertiary lymphatic structures and the maturity of the tertiary lymphatic structures are used to judge the degree of progression.